Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a
Saskia Koene1, Lara van Bon2, Enrico Bertini3
1Radboud Center for Mitochondrial Medicine, Department of Paediatrics, Radboudumc, Nijmegen, The Netherlands. Saskia.koene@radboudumc.nl.
Insights
This study proposes standardized outcome measures for pediatric mitochondrial diseases. These measures are crucial for upcoming clinical trials evaluating new treatments for mitochondrial myopathy and encephalopathy.
Area of Science:
- Pediatric Neurology
- Rare Diseases
- Mitochondrial Medicine
Background:
- Mitochondrial diseases lack effective disease-modifying therapies, necessitating robust clinical trials.
- Sensitive and valid outcome measures are critical for assessing treatment efficacy in rare pediatric mitochondrial disorders.
- Current consensus on outcome measures for children with mitochondrial disease is lacking.
Framework:
- A two-day Delphi-based workshop convened experts to address this need.
- The workshop aimed to define a protocol for an international, multi-center natural history study in pediatric mitochondrial myopathy.
- It also focused on selecting appropriate outcome measures for a validation study in pediatric mitochondrial encephalopathy.
Implementation:
- The study proposes two distinct sets of outcome measures.
- These sets are tailored for a natural history study in children with mitochondrial myopathy.
- They are also designed for a proposed validation study in children with mitochondrial encephalopathy.
Implications:
- Standardized outcome measures will facilitate more reliable and comparable clinical trial results.
- This work supports the development of effective treatments for rare pediatric mitochondrial diseases.
- It provides a foundation for future research and therapeutic advancements in the field.
Abstract:
Although there are no effective disease-modifying therapies for mitochondrial diseases, an increasing number of trials are being conducted in this rare disease group. The use of sensitive and valid endpoints is essential to test the effectiveness of potential treatments. There is no consensus on which outcome measures to use in children with mitochondrial disease. The aims of this two-day Delphi-based workshop were to (i) define the protocol for an international, multi-centre natural history study in children with mitochondrial myopathy and (ii) to select appropriate outcome measures for a validation study in children with mitochondrial encephalopathy. We suggest two sets of outcome measures for a natural history study in children with mitochondrial myopathy and for a proposed validation study in children with mitochondrial encephalopathy.
More Related Videos
06:15Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
09:18Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Related Concept Videos
Animal Mitochondrial Genetics
Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes
Internal Energy
Internal Energy
Internal Receptors
Predicting Reaction Outcomes
